A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab

NCT04869358 ·Status: COMPLETED ·Phase: PHASE4

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

NCT04834401 ·Status: COMPLETED

Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis

NCT06644638 ·Status: COMPLETED

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

COVID-19 Vaccine Response in Treated MS Patients

NCT05060354 ·Status: COMPLETED

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

NCT04796584 ·Status: TERMINATED

Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice

NCT06737419 ·Status: COMPLETED

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

NCT06897657 ·Status: COMPLETED

Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab

NCT04837651 ·Status: COMPLETED

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

NCT00640328 ·Status: COMPLETED ·Phase: PHASE2

Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.

NCT05576779 ·Status: COMPLETED

Covid-19 Vaccine Immune Response in Multiple Sclerosis

NCT05269888 ·Status: ACTIVE_NOT_RECRUITING

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

NCT00239655 ·Status: TERMINATED ·Phase: PHASE2

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

NCT04682548 ·Status: COMPLETED

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

NCT04510220 ·Status: COMPLETED ·Phase: PHASE3

Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study

NCT05197699 ·Status: TERMINATED

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

NCT04788615 ·Status: COMPLETED ·Phase: PHASE3

COVID-19 Vaccine Biomarker Study in Multiple Sclerosis

NCT05121662 ·Status: COMPLETED

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT01457924 ·Status: COMPLETED ·Phase: PHASE2

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

NCT06869785 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

NCT04964700 ·Status: UNKNOWN

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

NCT04486716 ·Status: COMPLETED ·Phase: PHASE3

Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS

NCT04838015 ·Status: UNKNOWN

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

NCT06167642 ·Status: ENROLLING_BY_INVITATION

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

NCT05834855 ·Status: RECRUITING ·Phase: PHASE3